China Sets Clinical Trial Record But Starting Studies Can Be Challenging
Innovation Drive Meets Economic Downturn
Antibody-drug conjugates, GLP-1 receptor agonists and cell/gene therapies propelled a big increase in clinical trial registrations in China last year, but why do sponsors sometimes remain reluctant to actually start studies?
